8-K: Sight Sciences Announces Preliminary Q4 and Full Year 2024 Financial Highlights

Sight Sciences reports preliminary unaudited financial results for Q4 and full year 2024, showing mixed performance with growth in surgical glaucoma offset by a decline in dry eye revenue.

Summary

• Sight Sciences announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 2024 total revenue is expected to be between $18.9 million and $19.1 million, a 1% increase year-over-year at the midpoint.
• Surgical Glaucoma revenues for Q4 are expected to be between $18.7 million and $18.8 million, a 9% increase year-over-year at the midpoint.
• Dry Eye revenues for Q4 are expected to be between $0.2 million and $0.3 million, compared to $1.6 million in the prior year period.
• Full year 2024 total revenue is expected to be between $79.7 million and $79.9 million, a 2% decrease year-over-year at the midpoint.
• Surgical Glaucoma revenues for the full year are expected to be between $75.8 million and $75.9 million, a 2% increase year-over-year at the midpoint.
• Dry Eye revenues for the full year are expected to be between $3.9 million and $4.0 million, compared to $6.7 million in 2023.
• The company's cash and cash equivalents as of December 31, 2024, were approximately $120 million, compared to $118.6 million as of September 30, 2024.
• Cash generated in the quarter totaled approximately $1.4 million, compared to cash used of $6.4 million in the same period of the prior year.
• Cash used during the year totaled approximately $18.1 million, down from $46.9 million cash used in the prior year.
• The company aims to achieve cash flow breakeven without raising additional equity capital.
• Complete Q4 and full year 2024 financial results are expected to be announced in March 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company highlights positive aspects like cash management and growth in surgical glaucoma, the overall revenue decline and challenges with dry eye revenue and reimbursement policies temper the outlook.

Positives

• Surgical Glaucoma revenue is increasing, with a 9% increase expected in Q4.
• The company has a strong cash position of approximately $120 million.
• Cash usage has been significantly reduced compared to the prior year.
• Sight Sciences is aiming for cash flow breakeven without additional equity raises.

Negatives

• Total revenue for the full year 2024 is expected to decrease by 2%.
• Dry Eye revenues have significantly declined, both in Q4 and for the full year.
• The company's results were below expectations due to new LCDs by Medicare contractors restricting coverage for multiple MIGS procedures.

Risks

• The preliminary financial results are unaudited and subject to change.
• New LCDs by Medicare contractors are negatively impacting revenue.
• The company's ability to achieve cash flow breakeven is dependent on executing its long-term vision.
• The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements, as detailed in their SEC filings.

Future Outlook

The company believes it is well-positioned to execute on its long-term vision with a strong cash position and clinically differentiated technologies, and aims to achieve cash flow breakeven without raising additional equity capital.

Management Comments

• Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences, stated that the results were below expectations due to the impact of new LCDs by Medicare contractors.
• He also mentioned that the company prioritized effective cash management in 2024 while continuing to invest in key long-term value drivers.
• Badawi believes the company is well-positioned to execute on its long-term vision with a strong cash position and progress towards establishing equitable reimbursed market access for TearCare.

Industry Context

Sight Sciences operates in the eyecare technology market, focusing on glaucoma and dry eye treatments. The announcement highlights the impact of reimbursement policies (LCDs) on the adoption of MIGS procedures, a key factor influencing the company's performance. The company competes with other companies in the glaucoma and dry eye space, such as Glaukos, Iridex, and Allergan.

Comparison to Industry Standards

• Glaukos, a major competitor in the MIGS market, has also faced challenges related to reimbursement and market access, indicating that the issues Sight Sciences is facing are not unique to the company.
• Compared to companies like Iridex, which focuses on laser-based solutions for glaucoma, Sight Sciences' OMNI system offers a different approach, potentially appealing to a different segment of surgeons.
• Allergan (now part of AbbVie) has a significant presence in the dry eye market with products like Restasis and Xiidra, setting a high bar for market penetration and acceptance that Sight Sciences' TearCare system aims to achieve.

Stakeholder Impact

• Shareholders may be concerned about the decline in total revenue and the challenges in the dry eye segment.
• Employees may be affected by the company's efforts to manage cash and achieve cash flow breakeven.
• Customers (physicians) may be impacted by changes in reimbursement policies and the availability of coverage for MIGS procedures.

Next Steps

• The company expects to announce complete fourth quarter and full year 2024 financial results in March 2025.

Key Dates